[
    [
        {
            "time": "",
            "original_text": "贝达药业通过港交所聆讯，恩沙替尼有望成公司首个出海品种！",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港交所",
                    "聆讯",
                    "恩沙替尼",
                    "出海品种"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业通过港交所聆讯，恩沙替尼有望成公司首个出海品种！",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)：刊发H股发行聆讯后资料集",
            "features": {
                "keywords": [
                    "贝达药业",
                    "H股",
                    "聆讯后资料集"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：刊发H股发行聆讯后资料集",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药周报：骨修复材料市场增速近20% 人工材料为骨移植的新选择",
            "features": {
                "keywords": [
                    "骨修复材料",
                    "市场增速",
                    "人工材料",
                    "骨移植"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药周报：骨修复材料市场增速近20% 人工材料为骨移植的新选择",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "A股异动|贝达药业(300558.SZ)涨4.44%通过港交所上市聆讯",
            "features": {
                "keywords": [
                    "贝达药业",
                    "A股",
                    "异动",
                    "港交所",
                    "聆讯"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股异动|贝达药业(300558.SZ)涨4.44%通过港交所上市聆讯",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "快讯 | 贝达药业通过港交所上市聆讯，目前已两款靶向创新药上市",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港交所",
                    "聆讯",
                    "靶向创新药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "快讯 | 贝达药业通过港交所上市聆讯，目前已两款靶向创新药上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业通过港交所聆讯，国内肺癌靶向药市场排名第一",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港交所",
                    "聆讯",
                    "肺癌靶向药",
                    "市场排名"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业通过港交所聆讯，国内肺癌靶向药市场排名第一",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "港股IPO|贝达药业通过聆讯，收入主要来源抗癌药的销售",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港股IPO",
                    "聆讯",
                    "抗癌药",
                    "销售"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "港股IPO|贝达药业通过聆讯，收入主要来源抗癌药的销售",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：恩沙替尼一线治疗ALK突变NSCLC的国际多中心三期临床研究目前正常推进中",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩沙替尼",
                    "ALK突变",
                    "NSCLC",
                    "临床研究"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：恩沙替尼一线治疗ALK突变NSCLC的国际多中心三期临床研究目前正常推进中",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[新股IPO]贝达药业已通过港交所上市聆讯",
            "features": {
                "keywords": [
                    "贝达药业",
                    "新股IPO",
                    "港交所",
                    "聆讯"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[新股IPO]贝达药业已通过港交所上市聆讯",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "港交所文件：制药企业贝达药业股份有限公司通过港交所上市聆讯",
            "features": {
                "keywords": [
                    "贝达药业",
                    "港交所",
                    "聆讯",
                    "制药企业"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "港交所文件：制药企业贝达药业股份有限公司通过港交所上市聆讯",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[IPO追踪]贝达药业通过上市聆讯传集资达78亿元",
            "features": {
                "keywords": [
                    "贝达药业",
                    "IPO追踪",
                    "上市聆讯",
                    "集资"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[IPO追踪]贝达药业通过上市聆讯传集资达78亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]